Determination of daptomycin in human plasma by liquid chromatography-tandem mass spectrometry. Clinical application

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 1, 2011, Pages 69-75

  Verdier, Marie Clémence ^a,b   Bentué Ferrer, Danièle ^a,b,c   Tribut, Olivier ^a   Collet, Nicolas ^a   Revest, Matthieu ^c   Bellissant, Eric ^a,b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b INSERM   (France)

^c RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Daptomycin; Liquid chromatography tandem mass spectrometry; Therapeutic drug monitoring

Indexed keywords

ACETONITRILE; DAPTOMYCIN; FORMIC ACID; RESERPINE; WATER;

ARTICLE; BLOOD SAMPLING; DILUTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; ELECTROSPRAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; PRECIPITATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAPTOMYCIN; DRUG MONITORING; DRUG STABILITY; HUMANS; MIDDLE AGED; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; TANDEM MASS SPECTROMETRY;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; POSIBACTERIA;

EID: 79953138026     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.005     Document Type: Article

References (30)

1. Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 2005;55:283-8. (Pubitemid 40425449)
2. Enoch DA, Bygott JM, Daly ML, Karas JA. Daptomycin. J Infect 2007;55:205-13. (Pubitemid 47248484)
3. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology 2008;81:79-91. (Pubitemid 351182681)
4. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 2006;12:844-52. (Pubitemid 44151284)
5. Seaton RA. Daptomycin: rationale and role in the management of skin and soft tissue infections. J Antimicrob Chemother 2008;62(Suppl 3):15-23.
6. Levine DP. Clinical experience with daptomycin: bacteremia and endocarditis. J Antimicrob Chemother 2008;62(Suppl 3):35-9.
7. Woodworth JR, Nyhart EH, Brier GL, Wolny JD, Black HR. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother 1992;36:318-25.
8. Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 2002;46:31-3. (Pubitemid 34031598)
9. Rybak MJ, Bailey EM, Lamp KC, Kaatz GW. Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for Gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother 1992;36:1109-14.
10. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003;47:1318-23. (Pubitemid 36368592)
11. DeRyke CA, Sutherland C, Zhang B, Nicolau DP, Kuti JL. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob Agents Chemother 2006;50:3529-34. (Pubitemid 44684861)
12. Martens-Lobenhoffer J, Kielstein JT, Oye C, Bode-Böger SM. Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma. J Chromatogr B 2008;875:546-50.
13. Gikas E, Bazoti FN, Fanourgiakis P, Perivolioti E, Roussidis A, Skoutelis A, et al. Simultaneous quantification of daptomycin and rifampicin in plasma by ultra performance liquid chromatography: application to a pharmacokinetic study. J Pharm Biomed Anal 2009;51:901-6.
14. Baietto L, D'Avolio A, De Rosa FG, Silvia Garazzino S, Michelazzo M, Ventimiglia G, et al. Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. Anal Bioanal Chem 2010;396:791-8.
15. John AK, Baldoni D, Haschke M, Rentsch K, Schaerli P, Zimmerli W, et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother 2009;53:2719-24.
16. U.S. Department of Health and Human Services. Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for Industry, Bioanalytical Method Validation, 2001. Available at: http://www.fda.gov/CDER/GUIDANCE/4252fnl.pdf.
17. Causon R. Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. J Chromatogr B 1997;689:175-80. (Pubitemid 27089650)
18. Van Eeckhaut A, Lanckmans K, Sarre S, Smolders I, Michotte Y. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects. J Chromatogr B 2009;877:2198-207.
19. Beiras-Fernandez A, Kur F, Kiefer S, Sodian R, Schmoeckel M, Weis M, et al. Multidrug-resistant Gram-positive infections in patients with ventricular assist devices: the role of daptomycin. Transplant Proc 2009;41:2589-91.
20. Benvenuto M, Benzinger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50:3245-9. (Pubitemid 44527494)
21. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006;44:655-6. (Pubitemid 43222276)
22. Marty FM, Yeh WW, Wennersten CB, Venkataraman L, Albano E, Alyea EP, et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillinresistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 2006;44:595-7. (Pubitemid 43224254)
23. Burkhardt O, Joukhadar C, Traunmüller F, Hadem J, Welte T, Kielstein JT. Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother 2008;61:224-5.
24. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob Antimicrob Agents Chemother 2004;48:2799-807. (Pubitemid 38989139)
25. Gu JQ, Nguyen KT, Gandhi C, Rajgarhia V, Baltz RH, Brian P, et al. Structural characterization of daptomycin analogues A21978C1-3(D-Asn11) produced by a recombinant Streptomyces roseosporus strain. J Nat Prod 2007;70:233-40. (Pubitemid 46447636)
26. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004;48:63-8. (Pubitemid 38040177)
27. Mohr JF, Wanger A, Rex JH. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial Gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis 2004;18:125-30. (Pubitemid 38221508)
28. Newell KA, Millis JM, Arnow PM, Bruce DS, Woodle ES, Cronin DC, et al. Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation 1998;65:439-42. (Pubitemid 28095979)
29. Sherman-Weber S, Axelrod P, Suh B, Rubin S, Beltramo D, Manacchio J, et al. Infective endocarditis following orthotopic heart transplantation: 10 cases and a review of the literature. Transpl Infect Dis 2004;6:165-70. (Pubitemid 40516684)
30. Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif 2006;24:548-54. (Pubitemid 46030098)